<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) often transform into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (AL-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), although its prognostic details have not been examined thoroughly </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively analyzed the prognosis of 189 AL-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Ninety-four patients received best supportive care (BSC), and 94 patients received disease-modifying therapies (<z:chebi fb="12" ids="28969">DMT</z:chebi>) that included chemotherapy (CHT) for 65 patients, allogeneic stem-cell transplantation (allo-SCT) for 21 patients, and other therapies for 8 patients </plain></SENT>
<SENT sid="3" pm="."><plain>The median survival time was 142 days </plain></SENT>
<SENT sid="4" pm="."><plain>In patients treated with BSC, platelet count alone was an independent prognostic factor </plain></SENT>
<SENT sid="5" pm="."><plain>In younger patients treated with <z:chebi fb="12" ids="28969">DMT</z:chebi> (&lt;60 years, N=25), allo-SCT was an independent prognostic factor associated with longer survival </plain></SENT>
<SENT sid="6" pm="."><plain>In older patients treated with <z:chebi fb="12" ids="28969">DMT</z:chebi> (â‰¥60 years, N=69), the therapy type did not affect survival, and performance status and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-specific comorbidity index were independent prognostic factors </plain></SENT>
</text></document>